Isatuximab for the treatment of relapsed/refractory multiple myeloma
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- Keywords
- CD38, isatuximab, monoclonal antibody, multiple myeloma, relapsed/refractory,
- MeSH
- Drug Resistance, Neoplasm drug effects MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Lenalidomide therapeutic use MeSH
- Humans MeSH
- Neoplasm Recurrence, Local drug therapy pathology MeSH
- Multiple Myeloma drug therapy pathology MeSH
- Antineoplastic Agents, Immunological therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Recurrence MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antibodies, Monoclonal, Humanized MeSH
- isatuximab MeSH Browser
- Lenalidomide MeSH
- Antineoplastic Agents, Immunological MeSH
INTRODUCTION: Although new drug classes have significantly extended survival of patients with multiple myeloma, they continue to experience multiple relapses and/or become refractory to treatment. Therefore, novel therapies and treatment combinations with different mechanisms of action are needed to improve the outcomes of patients with relapsed/refractory multiple myeloma. AREAS COVERED: Here, the authors review the published data regarding the development and clinical investigation of isatuximab, a CD38 monoclonal antibody, for treatment of patients with relapsed/refractory multiple myeloma. The mechanisms of action, clinical efficacy, and safety of isatuximab treatment are summarized. EXPERT OPINION: Isatuximab is approved in combination with pomalidomide/dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab displays a manageable safety profile, with infusion reactions being the most common adverse events. Isatuximab is currently being further evaluated in combination with other backbone regimens in relapsed/refractory and newly diagnosed multiple myeloma.
References provided by Crossref.org
